Related Experiment Video
Updated: Aug 15, 2026

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
Multidrug resistance-related phenotype and apoptosis-related protein expression in ovarian serous carcinomas
Evgeny Yakirevich1, Edmond Sabo, Inna Naroditsky
1Department of Pathology, Carmel Medical Center and Rappaport Faculty of Medicine, Technion University, Haifa, Israel. eyakirevich@lifespan.org
Objective:
Multidrug resistance (MDR) to chemotherapy is a major obstacle in attempts to improve the clinical outcome of ovarian carcinoma patients. The MDR-related phenotype is associated with over-expression of certain drug transporters, such as P-glycoprotein (P-gp), multidrug resistance protein 1 (MRP1), and lung resistance protein (LRP). The aim of this study was to evaluate the extent and prognostic significance of MDR-related protein expression in ovarian serous carcinomas. In addition, we correlated expression of these proteins with the apoptosis-related proteins p53, bcl-2, and bax.
Methods:
Consecutive sections from 60 cases of ovarian serous carcinoma were assessed immunohistochemically for expression of P-gp, MRP1, LRP, p53, bcl-2, and bax. The level of protein expression was scored based on staining intensity and extent.
Results:
Strong P-gp expression was observed in 12 (20%), MRP1 in 39 (65%), LRP in 27 (45%), p53 in 45 (75%), bcl-2 in 25 (41.7%), and bax in 30 (50%) of the 60 tumors. MRP1 expression was associated with both p53 and bcl-2 expressions (P = 0.01 and P = 0.03, respectively). Univariate analysis of survival revealed a significant inverse correlation between P-gp expression and patient survival (P = 0.015). Moreover, P-gp expression was significantly increased in tumors of patients unresponsive to chemotherapy (P = 0.009). Multivariate analysis revealed that only FIGO stage and P-gp expression were useful negative independent predictors of survival (P = 0.035 and P = 0.045, respectively).
Conclusions:
Our pilot study demonstrates that P-gp expression may be a reliable independent prognostic factor of survival in patients with ovarian serous carcinoma. Moreover, P-gp immunostaining may be useful for dividing ovarian carcinoma patients into chemoresponsive and chemoresistant groups.
Insights
Multidrug resistance (MDR) in ovarian cancer is linked to drug transporter proteins. P-glycoprotein (P-gp) expression is a significant predictor of poor survival and chemotherapy resistance in ovarian serous carcinoma patients.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Multidrug resistance (MDR) hinders effective chemotherapy for ovarian carcinoma.
- MDR is often associated with the overexpression of drug transporters like P-glycoprotein (P-gp), multidrug resistance protein 1 (MRP1), and lung resistance protein (LRP).
Purpose of the Study:
- To assess the prevalence and prognostic value of MDR-related proteins (P-gp, MRP1, LRP) in ovarian serous carcinomas.
- To correlate the expression of these proteins with apoptosis-related markers (p53, bcl-2, bax).
Main Methods:
- Immunohistochemical analysis of 60 ovarian serous carcinoma tissues.
- Quantification of P-gp, MRP1, LRP, p53, bcl-2, and bax protein expression levels.
- Statistical analysis including univariate and multivariate survival analyses.
Main Results:
- High expression rates were observed for MRP1 (65%), p53 (75%), LRP (45%), bax (50%), and bcl-2 (41.7%).
- P-gp expression showed a significant inverse correlation with patient survival (P=0.015) and was higher in chemotherapy-unresponsive tumors (P=0.009).
- Multivariate analysis identified FIGO stage and P-gp expression as independent negative predictors of survival.
Conclusions:
- P-glycoprotein (P-gp) expression is a potential independent prognostic factor for survival in ovarian serous carcinoma.
- P-gp immunostaining can help differentiate between chemoresponsive and chemoresistant patient groups.
Related Concept Videos
The Intrinsic Apoptotic Pathway
Treatment Resistant Cancers
Caspases

